Breast Cancer Clinical Trial
High-intensity Exercise After Treatment
Summary
This pilot study tests the feasibility and preliminary efficacy of an 8-week, 3-arm pilot exercise trial in which 45 breast cancer survivors will be randomized to high-intensity interval training (HIIT; n=15), moderate-intensity aerobic training (MOD; n=15), or Usual Care (UC; n=15).
Full Description
Aim 1: Determine the feasibility and acceptability of an 8-week high-intensity interval training (HIIT) program compared with a standard moderate-intensity aerobic training (MOD) program in 45 breast cancer survivors prescribed aromatase inhibitors.
Aim 2: Calculate effect sizes associated with the 8-week HIIT program, compared with MOD and Usual Care (UC), on cognitive and cardiovascular functions in 45 breast cancer survivors.
Eligible individuals will be women diagnosed with Stages I-IIIa breast cancer, have completed primary treatment (i.e., surgery, chemotherapy, and/or radiation therapy), and currently prescribed an aromatase inhibitor. The specific aims are: 1) Determine the feasibility and acceptability of an 8-week high-intensity interval training (HIIT) program compared with a standard moderate-intensity (MOD) program; and 2) Calculate effect sizes associated with the 8-week HIIT program, compared with MOD and usual care (UC), on cognitive and cardiovascular functions. Cognitive function is operationalized as performance on executive function and working memory tasks. Cardiovascular function is operationalized as exercise capacity (VO2peak, heart rate recovery), resting function (heart rate, blood pressure), and cardiovascular structure/function (arterial stiffness, arterial wall thickness, endothelial function). Associations between change in cardiovascular outcomes and change in cognitive outcomes across the intervention period will also be explored.
Eligibility Criteria
Inclusion Criteria:
Adult female (aged 19 or older)
First, primary diagnosis of Stage I-IIIa breast cancer
Hormone receptor positive (ER+ and/or PR+) diagnosis
Human epidermal growth factor receptor 2 negative (HER2-) diagnosis
Completed primary adjuvant treatment (i.e., surgery, chemotherapy, and/or radiation therapy)
Currently prescribed an aromatase inhibitor
No evidence of possible cognitive impairment as assessed using the Telephone Interview of Cognitive Status (TICS-M; score >21)
Sedentary except for casual lifestyle recreation. This is defined as self-reporting 20+ minutes of exercise physical activity on 2 or fewer days per week within the previous six months.
Receive physician's clearance to participate in an exercise program
Agree to be randomized
Fully vaccinated for COVID-19 ≥2 weeks prior to participation
Provide written informed consent to participate in study
Exclusion Criteria:
Males.
Stage 0 breast cancer diagnosis or metastatic disease
Currently receiving chemotherapy or radiation therapy for any cancer
Scheduled to receive breast surgery (e.g., mastectomy, reconstructive surgery) during the study period
Second cancer diagnosis (excluding non-invasive skin cancers; including breast cancer recurrence)
Self-report an 20+ minutes of exercise physical activity on 3+ days per week for the previous 6 months
Pregnant or plan to become pregnant during study period.
Is not cleared to participate in exercise by a physician.
Enrolled in another physical activity program
Unable to cycle on a stationary bike
Unwilling to complete study requirements
History of stroke, transient ischemic attack, other neurological disorders, or brain surgery involving tissue removal
Clinically significant TICS-M score (<21) during baseline procedures
Not fully vaccinated for COVID-19
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Omaha Nebraska, 68198, United States
How clear is this clinincal trial information?